Dianthus Therapeutics, Inc. /DE/ Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2021 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Dianthus Therapeutics, Inc. /DE/ quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2021 to Q3 2024.
  • Dianthus Therapeutics, Inc. /DE/ Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2024 was $1.39M, a 499% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $1.39M +$1.16M +499% Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $840K Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $435K Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $294K -$4.41M -93.7% Dec 31, 2023 10-Q 2024-11-07
Q3 2023 $232K Sep 30, 2023 10-Q 2023-11-09
Q4 2022 $4.7M +$4.23M +902% Dec 31, 2022 10-K 2024-03-21
Q4 2021 $469K Dec 31, 2021 8-K 2023-12-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.